The OCEAN(a)-DOSE trial investigated a subcutaneous injection of 225mg of olpasiran (formerly AMG 890) given once every 12 weeks in 281 patients with elevated Lp(a) and evidence of atherosclerotic ...
Some results have been hidden because they may be inaccessible to you